S-430 Effect of dapagliflozin on metabolic parameters in patient with diabetes = S-430 Effect of dapagliflozin on metabolic parameters in patient with diabetes

다국어 초록 (Multilingual Abstract)

Introduction: Sodium-glucose cotransporter-2 (SGLT2) inhibitor is a novel therapeutic strategy in patients with diabetes mellitus. Due to SGLT2 inhibitor’s novel glucose lowering mechanism and beneficial CV outcome, the proportion of diabetic patients using SGLT2 inhibitor is increasing. Dapagliflozin is one of the most commonly used SGLT2 inhibitor. The aim of our study is to measure a clinical effect of dapagliflozin in Korean patients. Method Subjects who visited Seoul St. Mary’s hospital from December 2014 to April 2015 and used dapagliflozin were enrolled in the study (n＝194). Height, body weight, blood pressure FBS, PP2hr, HbA1c, total cholesterol, triglyceride, HDL, LDL, BUN, Cr., AST, ALT were measured. Patients who used dapagliflozin less than 3 months and those who failed visiting the clinic were excluded (n＝56). A total of 138 patients were retrospectively analyzed. Paired Student’s t-test was performed to compare the data before and after (3 and 6 month) using dapagliflozin. Result Systolic/diastolic blood pressure, body weight, HbA1c level, fasting plasma glucose, 2 hour postprandial glucose, BUN decreased after using dapagliflozin for 3 months (p＜0.05). Systolic/diastolic blood pressure, FBS remained decreased after 6 months usage of dapagliflozin (p＜0.05). Most of the changes were made in early 3months. Conclusion Dapagliflozin is associated with early decrease of systolic/diastolic blood pressure, fasting plasma glucose, body weight. The use of dapagliflozin should be encouraged in Korean subjects with diabetes mellitus. Large number prospective multicenter double blind randomized control trial would solidify our data.